Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Revotar Initiates Bimosiamose Phase II Clinical Trial
The trial is designed as a double-blind, placebo controlled, randomised, cross-over study comprising up to 60 non-smoking patients with moderate to severe COPD (GOLD II-III). Revotar said that
The trial is designed as a double-blind, placebo controlled, randomised, cross-over study comprising up to 60 non-smoking patients with moderate to severe COPD (GOLD II-III). Revotar said that
BioExx said that the previous concerns which were primarily caused by delays in receipt of certain valves and instruments have been resolved in all material respects allowing the
HGS said that the BLA submission includes the results of two pivotal Phase 3 clinical trials in autoantibody-positive patients with SLE showing that belimumab met its primary endpoint.
Dermacyte Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development at Oxygen Biotherapeutics. It uses the company’s patented Oxycyte technology, an
Excellagen is a fibrillar bovine Type I collagen-based topical gel (2.6% collagen concentration) that is formulated to include structural stabilizers, hydrolytic enzyme inhibitors, and bacteriostatic agents. Cardium said
The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as
Under the terms of the settlement, Endo and Penwest have agreed to grant Sandoz a license to sell a generic of Opana ER on September 15, 2012. Penwest
The compounds are functionally liver-selective Glucokinase Activators (GKAs), which represent a novel class of glucose-lowering agents for the treatment of diabetes. Through the license agreement, Forest is expected
Reportedly, the pivotal, international, multicenter Phase III clinical trial, called Admyre, is expected to enroll 300 patients in 60 medical centers across 20 countries (including the US, Europe,
proinnovera offers a full range of clinical research services for Phase I-IV clinical trials throughout Europe. proinnovera offers expertise in several therapeutic areas including dermatology, pain management, allergy/respiratory,